The short answer
Enteroendocrine cells detect nutrients through a defined set of transporters and receptors: SGLT1 for glucose, FFAR1 and FFAR4 for long-chain fatty acids, GPR119 for lipid derivatives, and FFAR2 and FFAR3 for the short-chain fatty acids produced by bacterial fermentation in the gut.
Key facts
- Glucose sensor
- SGLT1, sodium-coupled glucose transporter 1
- How glucose signals
- Electrogenic uptake, not metabolism
- Long-chain fatty acid receptors
- FFAR1 (GPR40) and FFAR4 (GPR120)
- Lipid derivative receptor
- GPR119
- Fermentation product receptors
- FFAR2 and FFAR3
- What FFAR2/3 detect
- Short-chain fatty acids from bacterial fermentation
- Documented roles in GLP-1 secretion
- GPR119, FFAR2 and FFAR3
- Review
- Reimann F, Gribble FM, J Diabetes Investig 2016 (PMID 27186350)
The question this library had not asked
There is a large body of work on what GLP-1 does once it is in circulation and comparatively little written for general readers on what causes it to be there. That is the wrong way round for understanding the class, because almost every claim about raising GLP-1 by dietary means is a claim about this machinery, and the machinery is specific enough to check those claims against.
Glucose is not sensed the way most explanations say
The intuitive account is that the cell takes up glucose, metabolises it, and the resulting rise in ATP triggers secretion, which is the mechanism that operates in the pancreatic beta cell. That is not the predominant route here. Reimann and Gribble describe a predominant role for electrogenic glucose uptake through sodium-coupled glucose transporter 1. SGLT1 carries glucose together with sodium ions, and it is the movement of that positive charge across the membrane that depolarises the cell and opens voltage-gated calcium channels. The signal is the current rather than the calorie. That distinction has a practical consequence: a substance that is transported by SGLT1 but poorly metabolised can still trigger secretion, and a sugar that is metabolised but not carried by SGLT1 may not.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Fat is sensed by receptors, not by absorption
Long-chain fatty acids are detected by two G-protein-coupled receptors on the cell surface, FFAR1 (also called GPR40) and FFAR4, also called GPR120. These are receptors in the ordinary sense: the fatty acid binds the outside of the protein and the protein signals inward. GPR119 responds to lipid-derived molecules including monoacylglycerols and the endogenous lipid oleoylethanolamide, and Reimann and Gribble note it has a clearly documented role in GLP-1 secretion specifically. Each of these has been pursued as a drug target on the reasoning that an agonist would raise endogenous GLP-1; none has produced a licensed weight-management medicine, which is itself informative.
The bacterial channel
FFAR2 and FFAR3 respond to short-chain fatty acids (acetate, propionate and butyrate), which are not dietary components in any direct sense. They are produced by bacterial fermentation of material the human small intestine cannot digest, principally in the colon. This is the mechanistic link between fermentable fibre and GLP-1 secretion, and it is an indirect one: the fibre is not detected, its bacterial breakdown products are. It also explains why the effect depends on which bacteria are present, and so why the same intake produces different results in different people.
Two cells, nearly the same sensors
GIP comes from K cells and GLP-1 from L cells, and in labelled models more than 80% of cells produce only one of the two hormones. Transcriptomic analysis shows a close relationship between small intestinal K and L cells, and the glucose-sensing mechanism appears similar in both, with SGLT1 predominant in each. Both express FFAR1 and FFAR4. Where they differ is in other lipid-sensing receptors: GPR119 and FFAR2/3 have documented roles in GLP-1 secretion, while agonists for the endocannabinoid receptor type 1 selectively inhibit GIP secretion. The authors' conclusion is that these subtle differences might be exploited to modulate one incretin rather than the other. That is an interesting idea given how much of this field concerns whether GIP agonism or antagonism is preferable alongside GLP-1.
What this does and does not license
It licenses specific statements about which stimuli engage which sensor. It does not license the leap that is usually made next, that engaging these sensors produces anything resembling the effect of a GLP-1 receptor agonist. That question is quantitative rather than mechanistic, and it is addressed separately. Nothing in this article concerns any product, and nothing supplied on this site acts on any of the receptors described here.
Quick reference
| Sensor | Detects | Mechanism | Cell type |
|---|---|---|---|
| SGLT1 | Glucose | Electrogenic co-transport with sodium | K and L cells |
| FFAR1 (GPR40) | Long-chain fatty acids | Cell-surface GPCR | K and L cells |
| FFAR4 (GPR120) | Long-chain fatty acids | Cell-surface GPCR | K and L cells |
| GPR119 | Lipid derivatives | Cell-surface GPCR | Documented for GLP-1 |
| FFAR2 / FFAR3 | Short-chain fatty acids | Cell-surface GPCR | Documented for GLP-1 |
| CB1 | Endocannabinoids | Selective inhibition | Largely GIP |
Frequently asked questions
Does eating fibre raise GLP-1?
The mechanism exists: fermentable fibre yields short-chain fatty acids which engage FFAR2 and FFAR3 on L cells. Whether that produces a meaningful change in circulating GLP-1 in a given person depends on the fibre, the microbiota and the transit, and the size of the effect is a separate question from whether the pathway is real.
Why has no GPR119 agonist become a drug?
Several were developed and none reached licensure for weight management. The general reason applies to this whole approach: stimulating endogenous secretion is bounded by how much hormone the cells can release and how fast DPP-4 destroys it, whereas a receptor agonist is bounded only by tolerability.
Is SGLT1 the same as the SGLT2 that diabetes drugs block?
They are related transporters with different distributions. SGLT2 does most of the glucose reabsorption in the kidney and is the target of the gliflozins; SGLT1 is prominent in the intestine and, as described here, in the nutrient sensing that triggers incretin release.
Can these sensors be engaged by non-nutrients?
Yes, and that is the basis of every attempt to drug them. A synthetic agonist at FFAR1 or GPR119 engages the sensor without supplying the nutrient, which is the aim of the strategy.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedReimann F, Gribble FM, Mechanisms underlying glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion - J Diabetes Investig 2016 (PMID 27186350)pubmed.ncbi.nlm.nih.gov
- PubMedParker HE et al., Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion - Br J Pharmacol 2012 (PMID 21718300)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- The Nerve That Reads GLP-1 Before the Blood DoesKnocking down GLP-1 receptors on vagal afferents changed meal size and gastric emptying but not long-term body weight. That distinction matters enormously.
- Why Where Bile Arrives Changes How Much GLP-1 Comes OutBile acids are signalling molecules as well as detergents. They act on a receptor on L cells, and delivering them further down the gut raises the response.
- Two Nearly Identical Cells Releasing Opposite-Tempered HormonesGIP and GLP-1 come from different cells that are transcriptomically close and share a glucose sensor. The differences between them are small but exploitable.
- The Gap Between a Meal Response and a DrugNative GLP-1 is released in bursts and destroyed within minutes. An agonist is present continuously for a week or more. The difference is not one of degree.
- The Randomisation Ratio Decides What a Trial Can SayTwo trials of the same combination allocated participants very differently. One can measure the components' contribution properly and the other cannot.